GGrantIndex
← Search

Microarray Core Facility

$397,328P30FY2007CANIH

University Of Southern California, Los Angeles CA

Investigators

Linked publications, trials & patents

Trial NCT07456436Trial NCT07339254Trial NCT07332312Trial NCT07312162Trial NCT07306338Trial NCT07279571Trial NCT07276048Trial NCT07259304Trial NCT07229443Trial NCT07186699Trial NCT07162194Trial NCT07082257Trial NCT07076147Trial NCT06500169Trial NCT06422455Trial NCT06420219Trial NCT06374251Trial NCT06338657Trial NCT06336928Trial NCT06336902Trial NCT06297265Trial NCT06191575Trial NCT06171607Trial NCT06132087Trial NCT06128525Trial NCT06067295Trial NCT06063928Trial NCT06063486Trial NCT06060873Trial NCT05989828Trial NCT05791448Trial NCT05786664Trial NCT05516485Trial NCT05514990Trial NCT05462561Trial NCT05340309Trial NCT04981834Trial NCT04941430Trial NCT04927559Trial NCT04832763Trial NCT04830735Trial NCT04752267Trial NCT04387084Trial NCT04387071Trial NCT04373044Trial NCT04318028Trial NCT04315701Trial NCT04162678Trial NCT03971266Trial NCT03921047Trial NCT03858205Trial NCT03789773Trial NCT03739801Trial NCT03698162Trial NCT03657641Trial NCT03594448Trial NCT03576963Trial NCT03568292Trial NCT03568266Trial NCT03563651Trial NCT03563352Trial NCT03552796Trial NCT03537690Trial NCT03519984Trial NCT03514927Trial NCT03492801Trial NCT03485794Trial NCT03412370Trial NCT03408561Trial NCT03353896Trial NCT03348137Trial NCT03344211Trial NCT03330821Trial NCT03300609Trial NCT03300401Trial NCT03284346Trial NCT03267680Trial NCT03257761Trial NCT03238664Trial NCT03234556Trial NCT03207854Trial NCT03176979Trial NCT03146871Trial NCT03137706Trial NCT03120390Trial NCT03111823Trial NCT03098277Trial NCT03092856Trial NCT03091842Trial NCT03091816Trial NCT03091803Trial NCT03057639Trial NCT03049618Trial NCT03042897Trial NCT02978846Trial NCT02970617Trial NCT02970045Trial NCT02968680Trial NCT02967380Trial NCT02960308

Abstract

DESCRIPTION (provided by applicant): The USC/Norris Comprehensive Cancer Center at the University of Southern California was founded in 1971 and has been continuously supported by a Cancer Center Core Support Grant since 1973. It has developed into a major regional and national resource for cancer research, treatment, prevention and education. Center facilities have been built and developed with support from the NCI, the University and the Kenneth Morris Jr. Cancer Hospital, which is an integral part of the Cancer Center. The Center underwent a major expansion with the addition of the Norman Topping Tower in 1996 and is currently building a third facility, the Harlyne Morris Translational Research Tower. The Center's 191 members are organized into five thematic and five translational research programs, including a "bridge" program in developmental therapeutics. The thematic programs are headed by senior investigators in the fields of molecular genetics, epigenetics and regulation, tumor microenvironment, cancer epidemiology and cancer control research. The translational programs, which provide focus to our multidisciplinary research efforts, are in developmental therapeutics, genitourinary cancers, gastrointestinal cancers, women's cancers and hematologic and viral-associated malignancies. This application is for: 1) partial salary support for the Center's senior leadership, who are responsible for planning and overseeing our research efforts; 2) support for program planning and evaluation to keep the Center at the forefront of cancer research; 3) support for the administrative infrastructure of the Center; 4) partial support for the Center's 13 shared resources which facilitate the conduct of our peer-reviewed research; and 5) support for developmental funds to help us recruit new investigators in areas we have targeted for expansion. Continued funding from the Cancer Center Core Support Grant will allow us to build on our strengths in basic and population-based research and to translate our underlying expertise into strong, peer-reviewed funded research programs focused on cancers of major consequence in this country. Cancer Center members currently hold grants totaling $91 million in direct costs, with $40 million of that coming from NCI (all exclusive of the CCSG).

View original record on NIH RePORTER →